Latest Share Purchase Plan News

Findi Ltd reports flat revenue and a 15% rise in EBITDA but swings to a $12.5 million net loss for FY2025, driven by strategic capital raises and refinancing in its Indian subsidiary.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.

Iltani Resources has launched a $1 million Share Purchase Plan (SPP) offering existing Australian and New Zealand shareholders the chance to buy shares at a 10.4% discount following a recent $1.8 million placement. The funds will support exploration at the Orient Project and general working capital.

TruScreen Limited has obtained a waiver from NZ RegCo allowing it to allot oversubscribed shares up to 10 business days after its capital raising offer closes, subject to shareholder approval. This move aims to streamline the company’s NZ$3 million placement and share purchase plan.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.

Euro Manganese has successfully closed a C$11.2 million financing round, attracting heavyweight investors including the European Bank for Reconstruction and Development and Eric Sprott. The funds will accelerate development of its Chvaletice Manganese Project, a critical European source of battery-grade manganese.

ALS Limited has successfully completed a $350 million institutional placement, issuing 21 million new shares to fund key laboratory upgrades and maintain financial flexibility. The company also launched a $40 million share purchase plan to further support its growth ambitions.